This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's (ABBV) Venclyxto Gets EU Nod for First-Line AML
by Zacks Equity Research
European Commission grants approval to AbbVie (ABBV)/Roche's Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
J&J's (JNJ) Multiple Sclerosis Drug Ponvory Gets EU Approval
by Zacks Equity Research
J&J's (JNJ) oral multiple sclerosis drug, Ponvory, receives approval in Europe after demonstrating superior efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo
by Zacks Equity Research
Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan
by Zacks Equity Research
AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.
J&J's (JNJ) Amivantamab Gets FDA Nod for Rare Lung Cancer
by Zacks Equity Research
With the FDA nod, J&J's (JNJ) Rybrevant becomes the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations.
Johnson & Johnson (JNJ) Stock Moves -0.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $170.96, marking a -0.06% move from the previous day.
Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.
Why Is Johnson & Johnson (JNJ) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent (EBS) Issues Plan to Resume Bayview Facility Operation
by Zacks Equity Research
Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.
Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
Bayer's (BAYRY) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bayer (BAYRY) beat estimates for earnings and revenues for the first quarter of 2021.
Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
by Sweta Jaiswal, FRM
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $167.77 in the latest trading session, marking a +1.55% move from the prior day.
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
Zacks Industry Outlook Highlights: Johnson & Johnson, AstraZeneca and Pfizer
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, AstraZeneca and Pfizer
3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.